In this study, we demonstrated that both first- (18F-flortaucipir) and second-generation tau-PET tracers (18F-MK6240 and 18F-RO948), previously reported [24], can distinguish patients with AD from cognitively normal individuals and patients with MCI from both normal controls and AD patients [24]. The gene discussed is MAPT; the disease is Alzheimer disease.